CARBAMAZEPINE EFFECTS ΟΝ HEPATIC FUNCTION
Abstract
Hepatic disorders consist the third adverse effect, following the ones on skin and blood, because of the CBZ metabolism which mainly occurs in liver. We have studied the clinical liver toxicity of 64 patients administered chronically CBZ as monopharmacy or in combination with other antiepileptic drugs. 23 of our patients were administered carbamazepine (CBZ), 19 carbamazepine and phenobarbital (CBZ-PB), 11 carbamazepine and hydantoin (CBZ-PH) and 11 a combination of all three, carbamazepine, phenobarbital and hydantoin (CBZ-PB-PH). We have measured alkaline phosphatase (ΑΡ), lactate dehydrogenase (LDH), transaminases (SGOT, SGPT), total proteins (ΤΡ), albumins (ALB) and globulins (GLB). As a result, we have fοuηd pathological rates of ΑΡ in 8 patients (35%), of LDH in 2 (9%), SGOT in 2 (9%) and GLB in 2 (9%) following CBZ administration as monotherapy. No relationship between the level of the CBZ derivative, namely 10,11-CBZE, and hepatic functίοn was found. Ιn additio n, never has there been a need for replacing or discontinuing tl1e CBZ administration on any of our patients, because the hepatic function strain was such, that the treatment was unaffected.References
William J.T., Caviness D.H.M.: Toxicities and adverse reactions of carbamazepine. Ιn: Α Textbook for the clinixal application of therapeutic drug monitoring, 1987: 212-213.
Orologas Α., Kapitzoglou - Logothetou V., Logothetis J.: Monitoring antiepileptic therapy by measurment of drug concentrations in the serum. The advandages of high pressure liquid chromatography. Proceedings of the IV south-east European Neuropsychiatric conference, 1985, 1: 122-132.
Orologas Α., Divanoglou D., Malaka-Labreli Α., Paschalidou Μ., Papadakos Α.: Estimation of αntiepileptic drugs in the serum with high pressure liquid chromatography and fluorescence polarization immunoassay. Neurochemistry International 1988, 13: 156.
Divanoglou D., Milonas Ι., Nathanael V., Orologas Α., Iliadis S., Theodoridou Κ.: Pharmacokinetic behaνior of Carbamazepine and its main metabolite 10,11-Epoxide in monotherapy or in combination with other antiepileptic drug. Epilepsia 1993, 34: 91.
Hoppener R.J., Kuyer Α., Meijer J.W.A., Halswan J.: Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980, 25: 674.
Shadwick D. et al. Serum anticonvulsant concentrations and the risk of drug iduced skin eruptions. J. Neurosurg. Psychiat. 1984, 47: 642-644.
Sillanpaa Μ.: Carbamazepine pharmacology and clinical use. Acta Neurol. Scand 1981, 88: 64.
Livingston S., Pauli L., Berman Μ.: Carbamazepine in epilepsy. Nine years follow-up study with special emphasis on untoward reaction. Diseases of the Nervous system 1974, 35: 103-107.
Aldenhovel H.G.: The influence of long-term anticonvulsant therapy witlh diphenyl hydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate, aminotransferase, alanine aminotransferase and alkaline phosphatase. Eur. Arch. Psychiatry Neurol. Science 1988, 237: 312-316.
Patsalos Ρ.Ν., Stephenson T.J., Κrishna S., Elyas Α., Lascelles Ρ.Τ., Wiles C.M.: Side effects induced by carbamazepine 10,11-epoxide. Lancet 1985, 496.
Kutt Η., Solomon G.E., Dhar Α.Κ., Reson S.R., Κrall R.L., Morsell P.L.: Effects of progabide on carbamazepine epoxide and carbamazepine concentrations in plasma. Epilepsia 1984, 25: 674.
Meijer J.W., Binnie GC.D., Deletz R.M., Parys J.A., Pawlikowski Ν.Κ.: Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet 1984, 1: 802.
Foster G.R., Golsin R.D. et al.: Liver damage in long-term anticonvulsive therapy: Α sereological and histological study. Q. J. Medicin 1991, 79: 318-322.
